[1
]
iMED Oncology, AstraZeneca, Macclesfield, United Kingdom. Darren.Cross@astrazeneca.com
pbdmpk@gmail.com.
[2
]
iMED Oncology, AstraZeneca, Cambridge, United Kingdom.
[3
]
Asia and Emerging Markets iMED, AstraZeneca, Shanghai, China.
[4
]
Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
[5
]
National Taiwan University Hospital, Taipei City, Taiwan.
[6
]
Global Medicines Development, AstraZeneca, Macclesfield, United Kingdom.
[7
]
iMED Oncology, AstraZeneca, Macclesfield, United Kingdom.
[8
]
AstraZeneca, Cambridge, United Kingdom.
[9
]
AstraZeneca Translational Science Centre, Stockholm, Sweden. Department of Clinical
Neuroscience, Karolinska Institutet, Stockholm, Sweden.
[10
]
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
[11
]
iMED Oncology, AstraZeneca, Gatehouse Park, Waltham, Massachusetts.
[12
]
Dana-Farber Cancer Institute, Boston, Massachusetts.
[13
]
iMED Oncology, AstraZeneca, Cambridge, United Kingdom. Darren.Cross@astrazeneca.com
pbdmpk@gmail.com.